Zoetis Inc.

ZTS · NYSE · USD

Can Zoetis defend its dermatology and parasiticide franchises against price-based competition until its next wave of innovation reaches the market in 2027 and 2028?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Livestock and diagnostics growth

    The bull case is that cattle, poultry, fish and diagnostics are growing fast enough to keep total revenue near flat while companion animal works through its downturn.

  • Long-acting OA pain launches

    New long-acting osteoarthritis products and a wider dermatology lineup give Zoetis fresh products to defend clinics where its older brands are losing ground.

  • Cost cuts and buybacks

    Cost cuts and a smaller share count from buybacks can keep earnings per share from falling as much as revenue, cushioning the downturn.

Bear case

  • Price-based competition

    The bear case is that new entrants are winning on price in a market that is no longer expanding, so Zoetis must discount to hold volume and loses revenue either way.

  • Falling clinic visits

    Pet owners are cutting routine clinic visits after several years of price increases, which shrinks the pool of new patients the companion animal franchises need.

  • Repeated guidance cuts

    Management has cut its outlook twice in a year and still assumes the pressure persists, with no evidence yet that the companion animal decline has found a floor.

  • Innovation arrives later

    The next wave of blockbuster products is years away, so results through 2027 depend on defending existing brands rather than on new launches.

Bull and bear points

Growth & Execution

In short: Livestock and diagnostics are growing while companion animal sales fall and guidance has been cut twice.

Bull · 2

  • Cattle, poultry and fish carry the portfolio as pets weaken

    Cattle revenue rose 21.9% in the second quarter, and management guides livestock to mid- to high-single-digit growth for the year, which offsets part of the companion animal decline.

    Filed financials

  • Long-acting OA products reach Europe and Canada

    Lenivia and Portela are approved and in early launch in the EU and Canada, giving the osteoarthritis franchise new products while U.S. Librela revenue has stopped falling sequentially.

    Q2 FY2026 call
Bear · 2

  • Full-year outlook flipped from growth to decline

    In February management guided 2026 to growth; in August it guided to a decline and said sales trends through July had not stabilized, which removes the idea of a second-half recovery.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Companion animal revenue is shrinking, not just slowing

    Dogs and cats revenue fell 4.8% year on year in the second quarter, with dermatology the weakest category and no sign of stabilization in the July sales trends management cited.

    Filed financials

Profitability & Financial Strength

In short: Margins and cash generation remain strong, but shareholder payouts now exceed free cash flow.

Bull · 1

  • Buybacks keep reducing the share count

    The diluted share count fell 5.6% over three years, so adjusted earnings per share still rose even as net income declined on weaker companion animal sales.

    Q2 FY2026 call
Bear · 1

  • Realized price is now expected to fall this year

    Management had guided price to its normal range; it now expects price flat to down as gross-to-net spending buys back volume, which reverses a long-standing source of growth.

    Tone shiftQ4 FY2025 → Q2 FY2026

Market Position

In short: Zoetis leads in dermatology and parasiticides, but new entrants are competing on price.

Bull · 2

  • Zoetis still holds the leading share of key categories

    U.S. dermatology share was about 86% and Simparica Trio held roughly 21% of in-clinic oral parasiticide share, nearly double its nearest competitor, so rivals must win patients one at a time.

    Q2 FY2026 call

  • No generic threat to core franchises before 2032

    Management does not expect generics in dermatology, pain or parasiticides for years, with Apoquel patents running to 2032, so competition comes from branded rivals rather than copycat pricing.

    Q1 FY2026 call
Bear · 2

  • Competition no longer expands the category

    Management once expected launch promotions to be short-lived and new entrants to grow the market; it now says entrants discount to take existing patients, making share loss harder to reverse.

    Tone shiftQ3 FY2025 → Q2 FY2026

  • Generics already eroding Cerenia and Convenia

    These two blockbuster products lost meaningful share to price-driven generic competition in the quarter and Zoetis cut their U.S. prices, showing how fast an off-patent brand can turn negative.

    Q2 FY2026 call